Abstract: The present invention relates to new vitamin D compounds which are bonded to a labelling group at the C3 stereocentre by means of a linker. The present invention further relates to a method for producing these vitamin D compounds and to the use of an intermediate for producing these compounds. The present invention also relates to a method for quantitatively determining vitamin D using a vitamin D compound according to the invention as a tracer. Furthermore, the present invention relates to a reagent for determining vitamin D, containing a compound according to the invention, and to the use thereof for determining vitamin D.

Abstract: The invention relates to methods for binding biologically active molecules to surfaces by coating the surface with a supported reagent in a first step and then covalently coupling said biologically active molecules to the supported reagent using a biorthogonal cycloaddition reaction. Fields of application of the invention include biochemical research, medical diagnostics and the pharmaceutical industry.

Abstract: The invention relates to methods, reagents and devices for detecting an analyte in a sample.

Abstract: The present invention relates to new vitamin D compounds which are bonded to a labelling group at the C3 stereocentre by means of a linker. The present invention further relates to a method for producing these vitamin D compounds and to the use of an intermediate for producing these compounds. The present invention also relates to a method for quantitatively determining vitamin D using a vitamin D compound according to the invention as a tracer. Furthermore, the present invention relates to a reagent for determining vitamin D, containing a compound according to the invention, and to the use thereof for determining vitamin D.

Abstract: The present invention relates to new vitamin D compounds which are bonded to a labelling group at the C3 stereocentre by means of a linker. The present invention further relates to a method for producing these vitamin D compounds and to the use of an intermediate for producing these compounds. The present invention also relates to a method for quantitatively determining vitamin D using a vitamin D compound according to the invention as a tracer. Furthermore, the present invention relates to a reagent for determining vitamin D, containing a compound according to the invention, and to the use thereof for determining vitamin D.

Abstract: The present invention relates to a method for releasing bound vitamin D by bringing a sample containing vitamin D into contact with a release reagent which contains at least one hydrotropic substance and at least one transition metal salt. The released vitamin D can subsequently be determined quantitatively. The present invention relates further to a reagent for releasing and optionally determining vitamin D, containing at least one hydrotropic substance and at least one transition metal salt, as well as to the use of such a release reagent for releasing and optionally determining vitamin D.

Abstract: The invention relates to methods for binding biologically active molecules to surfaces by coating the surface with a supported reagent in a first step and then covalently coupling said biologically active molecules to the supported reagent using a biorthogonal cycloaddition reaction. Fields of application of the invention include biochemical research, medical diagnostics and the pharmaceutical industry.

Abstract: The present invention relates to new vitamin D compounds which are bonded to a labelling group at the C3 stereocentre by means of a linker. The present invention further relates to a method for producing these vitamin D compounds and to the use of an intermediate for producing these compounds. The present invention also relates to a method for quantitatively determining vitamin D using a vitamin D compound according to the invention as a tracer. Furthermore, the present invention relates to a reagent for determining vitamin D, containing a compound according to the invention, and to the use thereof for determining vitamin D.

Abstract: The present invention relates to new vitamin D compounds which are bonded to a labelling group at the C3 stereocentre by means of a linker. The present invention further relates to a method for producing these vitamin D compounds and to the use of an intermediate for producing these compounds. The present invention also relates to a method for quantitatively determining vitamin D using a vitamin D compound according to the invention as a tracer. Furthermore, the present invention relates to a reagent for determining vitamin D, containing a compound according to the invention, and to the use thereof for determining vitamin D.

Abstract: The present invention relates to a method for releasing bound vitamin D by bringing a sample containing vitamin D into contact with a release reagent which contains at least one hydrotropic substance and at least one transition metal salt. The released vitamin D can subsequently be determined quantitatively. The present invention relates further to a reagent for releasing and optionally determining vitamin D, containing at least one hydrotropic substance and at least one transition metal salt, as well as to the use of such a release reagent for releasing and optionally determining vitamin D.

Abstract: The invention relates to methods, reagents and devices for detecting an analyte in a sample.

Abstract: The present invention relates to new pharmaceutical uses of 4-azasteroid compounds, in particular of Finasteride/Dutasteride/Dutasteride and Dutasteride, particularly preferred of Finasteride/Dutasteride/Dutasteride, and its pharmaceutically acceptable derivatives, and combinations comprising said compounds. The invention also features generally the use of a modulator compound of neuroprotective conditions via beta subunits of shaker-type voltage-gated potassium channels and/or via members of solute carriers family 25, in particular Aralar (member 12) and adenine-nucleotide translocators 1 & 2 (member 4 & 5) and/or via a 4-nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1 (NIPSNAP 1) as a neuroprotective medicament, particularly as a medicament for the prevention and/or treatment of neurological diseases such as dementia, Parkinson, Alzheimer, schizophrenia or epilepsy.

Abstract: The present invention relates to new pharmaceutical uses of 4-azasteroid compounds, in particular of Finasteride/Dutasteride/Dutasteride and Dutasteride, particularly preferred of Finasteride/Dutasteride/Dutasteride, and its pharmaceutically acceptable derivatives, and combinations comprising said compounds. The invention also features generally the use of a modulator compound of neuroprotective conditions via beta subunits of shaker-type voltage-gated potassium channels and/or via members of solute carriers family 25, in particular Aralar (member 12) and adenine-nucleotide translocators 1 & 2 (member 4 & 5) and/or via a 4-nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1 (NIPSNAP 1) as a neuroprotective medicament, particularly as a medicament for the prevention and/or treatment of neurological diseases such as dementia, Parkinson, Alzheimer, schizophrenia or epilepsy.

Abstract: The invention relates to a method for the enrichment, isolation and/or identification of cleavage products of at least one enzyme from a sample. According to the invention, an enzymatically inactive mutant of a protease is used as an affinity material, said mutant furthermore maintaining its specific substrate nature. At least one cleavage product of the protease of which the mutant is used, and at least one cleavage product of the enzyme of which the cleavage products are to be analyzed, comprise at least one structural similarity.

Abstract: The invention relates to a substance comprising a solid carrier that is connected to a spacer by means of a linker, said spacer comprising at least two defined groups. Said substance is suitable for using as an affinity material for enriching and/or isolating phosphorylated peptides and/or proteins. The inventive substance especially enables tyrosine-phosphorylated peptides and/or proteins to be enriched and/or isolated.